35.00
3.52 (11.18%)
| Previous Close | 31.48 |
| Open | 32.26 |
| Volume | 4,166,892 |
| Avg. Volume (3M) | 1,617,176 |
| Market Cap | 6,441,014,784 |
| Price / Earnings (Forward) | 1.00 |
| Price / Sales | 8.71 |
| Price / Book | 6.26 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 - 11 Aug 2025 |
| Profit Margin | -29.95% |
| Operating Margin (TTM) | -25.97% |
| Diluted EPS (TTM) | -1.18 |
| Quarterly Revenue Growth (YOY) | 107.50% |
| Total Debt/Equity (MRQ) | 35.65% |
| Current Ratio (MRQ) | 5.20 |
| Operating Cash Flow (TTM) | -263.30 M |
| Levered Free Cash Flow (TTM) | -202.32 M |
| Return on Assets (TTM) | -8.77% |
| Return on Equity (TTM) | -20.00% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Legend Biotech Corporation | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | 0.63 |
|
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 1.33% |
| % Held by Institutions | 47.77% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 84.00 (RBC Capital, 140.00%) | Buy |
| Median | 73.00 (108.57%) | |
| Low | 55.00 (Cantor Fitzgerald, 57.14%) | Buy |
| Average | 71.25 (103.57%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 30.89 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 14 May 2025 | 55.00 (57.14%) | Buy | 27.80 |
| Truist Securities | 14 May 2025 | 71.00 (102.86%) | Buy | 27.80 |
| RBC Capital | 22 Apr 2025 | 84.00 (140.00%) | Buy | 34.48 |
| HC Wainwright & Co. | 16 Apr 2025 | 75.00 (114.29%) | Buy | 33.46 |
| 08 Apr 2025 | 75.00 (114.29%) | Buy | 30.77 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Jun 2025 | Announcement | Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting |
| 22 May 2025 | Announcement | Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT |
| 22 May 2025 | Announcement | Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT |
| 19 May 2025 | Announcement | Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting |
| 13 May 2025 | Announcement | Legend Biotech Reports First Quarter 2025 Results and Recent Highlights |
| 29 Apr 2025 | Announcement | Legend Biotech to Host Investor Conference Call on First Quarter 2025 Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |